DrugPatentWatch Database Preview» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 7,955,597
|Title:||Anti-IL-6 antibodies, compositions, methods and uses|
|Abstract:||The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.|
|Inventor(s):||Giles-Komar; Jill (Downingtown, PA), Knight; David (Berwyn, PA), Peritt; David (Bala Cynwyd, PA), Trikha; Mohit (Paoli, PA)|
|Assignee:||Centocor, Inc. (Malvern, PA)|
|Patent Claims:||1. A method for inhibiting tumor growth in a cell, tissue, organ or animal, or inhibiting cancer cachexia in an animal, comprising contacting or administering to said cell,
tissue, organ or animal a pharmaceutically effective amount of an IL-6 antibody or fragment thereof comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:7, a light chain variable region having the amino acid sequence of
SEQ ID NO:8, and a constant region derived from one or more human antibodies.
2. A method according to claim 1, wherein said tumor or cancer is at least one selected from leukemia, acute leukemia, acute lymphoblastic leukemia, B-cell, T-cell or FAB acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, myelodyplastic syndrome, a lymphoma, Hodgkin's disease, a malignant lymphoma, non-hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, Kaposi's sarcoma, colorectal carcinoma, pancreatic carcinoma, renal cell carcinoma, prostatic cell carcinoma, nasopharyngeal carcinoma, malignant histiocytosis, paraneoplastic syndrome/hypercalcemia of malignancy, solid tumors, adenocarcinomas, sarcomas, and malignant melanoma.
3. A method according to claim 1 wherein said effective amount is 0.01-100 mg/kilogram of said cells, tissue, organ or animal.
4. A method according to claim 1, further comprising administering, prior, concurrently or after said contacting or administering, at least one composition comprising a therapeutically effective amount of at least one compound or protein selected from at least one of a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anethetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, a diabetes related agent, a mineral, a nutritional, a thyroid agent, a vitamin, a calcium related hormone, an antidiarrheal, an antitussive, an antiemetic, an antiulcer, a laxative, an anticoagulant, an erythropieitin, a filgrastim, a sargramostim, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, an estrogen receptor modulator, a mydriatic, a cycloplegic, an alkylating agent, an antimetabolite, a mitotic inhibitor, a radiopharmaceutical, an antidepressant, antimanic agent, an antipsychotic, an anxiolytic, a hypnotic, a sympathomimetic, a stimulant, donepezil, tacrine, an asthma medication, a beta agonist, an inhaled steroid, a leukotriene inhibitor, a methylxanthine, a cromolyn, an epinephrine or analog, dornase alpha, a cytokine, a cytokine antagonist.
5. A method for inhibiting tumor growth in a cell, tissue, organ or animal, or inhibiting cancer cachexia in an animal comprising contacting or administering to said cell, tissue, organ or animal a pharmaceutically effective amount of an isolated antibody or antibody fragment that binds to human IL-6, comprising the heavy chain and light chain complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOS:1-6, and a constant region derived from one or more human antibodies.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Amgen||NEUPOGEN||filgrastim||VIAL||103353||001||1991-02-20||Start Trial||Centocor, Inc. (Malvern, PA)||2039-03-29||RX||search|
|Amgen||NEUPOGEN||filgrastim||VIAL||103353||002||1991-02-20||Start Trial||Centocor, Inc. (Malvern, PA)||2039-03-29||RX||search|
|Amgen||NEUPOGEN||filgrastim||SYRINGE||103353||003||1991-02-20||Start Trial||Centocor, Inc. (Malvern, PA)||2039-03-29||RX||search|
|Amgen||NEUPOGEN||filgrastim||SYRINGE||103353||004||1991-02-20||Start Trial||Centocor, Inc. (Malvern, PA)||2039-03-29||RX||search|
|Berlex Labs||LEUKINE||sargramostim||VIAL||103362||001||1991-03-05||Start Trial||Centocor, Inc. (Malvern, PA)||2039-03-29||RX||search|
|Berlex Labs||LEUKINE||sargramostim||VIAL||103362||002||1991-03-05||Start Trial||Centocor, Inc. (Malvern, PA)||2039-03-29||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|World Intellectual Property Organization (WIPO)||2004039826||Start Trial|
|United States of America||2006188502||Start Trial|
|United States of America||2007292420||Start Trial|
|United States of America||2008312172||Start Trial|
|United States of America||2009291084||Start Trial|
|United States of America||2011218329||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.